Redmile Group’s Viking Therapeutics VKTX Stock Holding History

Redmile Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-16,260	Closed	-$112K	–	75
2019 Q3	$112K	Hold	16,260	–	–	﹤0.01%	73
2019 Q2	$135K	Hold	16,260	–	–	﹤0.01%	80
2019 Q1	$162K	Hold	16,260	–	–	﹤0.01%	79
2018 Q4	$124K	Sell	16,260 -13,740	-46%	-$164K	0.01%	74
2018 Q3	$523K	Buy	+30,000	New	+$357K	0.02%	71

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Redmile Group's VKTX Position: Q4 2019 in Review

Redmile Group sold out of Viking Therapeutics (VKTX) in Q4 2019, closing a stake of 16,260 shares — an estimated $112K sold.

Redmile Group first reported a position in VKTX in Q3 2018 and held it in 5 quarters. The position peaked at $523K in Q3 2018. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2019.

Redmile Group reported no remaining Viking Therapeutics position as of Q4 2019 after selling out during the quarter.
Redmile Group sold 16,260 Viking Therapeutics shares in Q4 2019, an estimated $112K.
Redmile Group first reported a position in Viking Therapeutics in Q3 2018 and held it in 5 quarters.
Redmile Group's Viking Therapeutics position peaked at $523K in Q3 2018.
143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2019.

Based on Redmile Group's 13F filing for Q4 2019, filed 14 Feb 2020.